Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial

Por Hitre, E, Budai, B, Takácsi-Nagy, Z, Rubovszky, G, Tóth, E, Remenár, É, Polgár, C, Láng, I
Publicado em 2013

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metasta...

Por Licitra, L., Mesia, R., Rivera, F., Remenár, É., Hitt, R., Erfán, J., Rottey, S., Kawecki, A., Zabolotnyy, D., Benasso, M., Störkel, S., Senger, S., Stroh, C., Vermorken, J. B.
Publicado em 2011

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/I...

Por Vermorken, J. B., Peyrade, F., Krauss, J., Mesía, R., Remenar, E., Gauler, T. C., Keilholz, U., Delord, J. P., Schafhausen, P., Erfán, J., Brümmendorf, T. H., Iglesias, L., Bethe, U., Hicking, C., Clement, P. M.
Publicado em 2014

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locor...

Por van Herpen, C M L, Mauer, M E, Mesia, R, Degardin, M, Jelic, S, Coens, C, Betka, J, Bernier, J, Remenar, E, Stewart, J S, Preiss, J H, van den Weyngaert, D, Bottomley, A, Vermorken, J B
Publicado em 2010